Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (103,126)	$ (146,872)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,050	1,754
Equity-based compensation	27,255	18,491
Amortization of investment premiums	(4,571)	2,426
Loss from equity method investment	3,048	2,745
Deferral of equity method investment intra-entity profit on sales	2,812	2,812
Change in fair value of contingent consideration	100	421
In-process research and development charge	0	55,990
Changes in operating assets and liabilities:
Accounts receivable	(1,138)	230
Prepaid expenses and other current assets	(4,815)	422
Operating lease right-of-use assets	4,658	2,671
Other assets	(393)	(918)
Accounts payable	1,170	(57)
Accrued expenses	(17,392)	(3,717)
Deferred revenue	(14,566)	(13,995)
Operating lease liabilities	(4,420)	(2,204)
Net cash used in operating activities	(109,328)	(79,801)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(3,832)	(1,429)
Purchases of marketable securities	(382,033)	0
Maturities of marketable securities	263,617	93,734
Acquired in-process research and development, net of cash acquired of $287	0	(44,832)
Net cash (used in) provided by investing activities	(122,248)	47,473
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from options exercised	755	8,435
Net cash provided by financing activities	2,221	47,320
Net (decrease) increase in cash and cash equivalents and restricted cash equivalents	(229,355)	14,992
Cash and cash equivalents and restricted cash equivalents, beginning of period	535,463	125,486	$ 125,486
Cash and cash equivalents and restricted cash equivalents, end of period	306,108	140,478	535,463
Reconciliation of cash and cash equivalents and restricted cash equivalents to condensed consolidated balance sheet:
Cash and cash equivalents	294,150	133,382	523,506
Restricted cash equivalents, included in investments and other assets	11,958	7,096
Total cash and cash equivalents and restricted cash equivalents	306,108	140,478	$ 535,463
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end	3,525	3,721
Shares issued for Rewrite research milestone liability	24,126	0
Contingent consideration liability assumed in asset acquisition	0	10,541
At The Market Offerings [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	$ 1,466	$ 38,885